COVID-19: Vaccines and Therapeutics
The Food and Drug Administration released briefing documents for the convening of the agency’s Vaccines and Related Biological Products Advisory Committee, which will consider COVID-19 vaccine booster shot applications from Moderna and Johnson & Johnson.
The Centers for Disease Control and Prevention has released an initial document intended to assist jurisdictions across the country in planning for the distribution and administration of COVID-19 vaccines to the pediatric population.
The American Medical Association Oct. 6 announced Current Procedural Terminology code set updates to now include vaccine and administration codes for pediatric doses of the Pfizer COVID-19 vaccine.
Merck announced its submission for a Food and Drug Administration emergency use authorization of its investigational oral antiviral COVID-19 medicine.
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response issued details on several key changes related to the REGEN-COV COVID-19 monoclonal antibody therapy.
Getting the COVID-19 and flu vaccines is safe and effective and may ease strain on hospital staff.
In Wyoming — where COVID-19 vaccination rates are low — Sheridan Memorial Hospital calls for more people to get vaccinated by sharing data on rising cases and hospitalizations, and the impact on its resources.
Pfizer announced that it has formally requested that the Food and Drug Administration amend its COVID-19 vaccine emergency use authorization to allow vaccinations of children between the ages of 5 and 11.
Johnson & Johnson announced its request that the Food and Drug Administration amend the current emergency use authorization for the J&J COVID-19 vaccine to include a booster dose.
AstraZeneca said it has requested an emergency use authorization from the Food and Drug Administration for its long-acting antibody combination for the prevention of symptomatic COVID-19.